New Delhi, Jan. 31 -- Biocon Biologics Ltd expects a significant rise in demand for its insulin products across geographies in the coming months and years, managing director and chief executive Shreehas Tambe said on Friday.

"What we are certainly seeing is an increasing demand for our insulin products.not just in the US and Europe but also in emerging markets," Tambe told Mint in an interview. "We consider diabetes and insulin particularly as a big differentiator [for us] because the world is going to need insulin and it's not going away," Tambe added.

Also Read | Biocon Biologics to sell India branded formulations biz to Eris for Rs.1,242 cr

Tambe said the company, a subsidiary of the Bengaluru-based Biocon Ltd, has five products in ...